STAT+: HIV resurgence is feared as global funding to combat the disease falls 18%
The world risks a resurgence of the HIV epidemic after international financing to combat the disease suffered a…
Read at source →Source
STAT News
Medicine, biotech, and health policy
Health · 283 articles · page 7 of 8 · fetched 14 minutes ago
STAT+: Pharma’s drug spending deflection
Job lock, surging prescription drug costs, No Surprises Act update, and more from STAT's Health Care Inc.
Read at source →
STAT+: Sarepta names Michael Severino, former Tessera CEO, as new chief executive
The beleaguered Sarepta Therapeutics named Michael Severino, who previously led Tessera Therapeutics, as its new CEO.
Read at source →
AdSponsoredSiguimi
Pure chronological social — no algorithm
See who you follow, newest first. Free to join. Posts that stay visible — not buried by an algo.
Join siguimi.com →
STAT+: Pharmalittle: We’re reading about a U.S. peptide panel’s votes, Amgen scuffling with the FDA, and more
An FDA panel recommended that compounding pharmacies be allowed to make two more peptides, a step toward RFK Jr.'s goal…
Read at source →
STAT+: Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug
Ahead of a hearing, the FDA raised questions about the benefits of a Duchenne treatment from Capricor Therapeutics,…
Read at source →
A trend that isn’t fading, ultra-processed baby foods
An FDA advisory panel serves some peptide wins, a measles record, and more health news from Morning Rounds
Read at source →
STAT+: RA Capital backs upstart rival to Ultragenyx and Ionis in rare brain disease
Oak Hill Bio, a new company backed by RA Capital and other investors, will take on Ultragenyx and Ionis in developing…
Read at source →
Opinion: E-bikes, e-scooters are a burgeoning pediatric public health emergency
“Emergency departments across America report dramatic increases in serious injuries from e-bikes and e-scooters,” write…
Read at source →
STAT+: As some medical schools embrace RFK Jr.’s nutrition push, they deftly sidestep MAHA priorities
Even as some medical schools heed health secretary Robert F. Kennedy Jr.’s call for more nutrition education, several…
Read at source →
Opinion: How midwives like me can help fight medical misinformation
“I have come to believe that changing a mind is rarely the point. Planting a seed is,” writes nurse-midwife Mara Evans.
Read at source →
STAT+: Argenx to buy Forte Biosciences for $2.2B
Argenx plans to buy Forte Biosciences for $2.2 billion, expanding its pipeline of drugs that could treat multiple…
Read at source →
Opinion: I led the FDA’s food safety and nutrition center. Here’s what people are missing about the cyclospora outbreak
“Consumers should not be faced with a trade-off between nutrition and food safety,” writes Susan Mayne, former director…
Read at source →
FDA advisory panel narrowly rejects compounding of one peptide, backs two others
Robert F. Kennedy Jr. has lauded peptides and said he takes them himself.
Read at source →
There are already more U.S. measles cases this year than in all of 2025
The number of measles cases in the U.S. has surpassed the record-breaking tally for all of 2025, with five more months…
Read at source →
STAT+: Up and down the ladder: The latest comings and goings
From new hires to departures, promotions, and hires, here are the latest comings and goings in the pharma industry.
Read at source →
STAT+: Fatal gene-editing trial in China raises ethics and oversight questions
Sanofi insulin pen in short supply, a win for peptide compounds, and more biotech news from The Readout
Read at source →STAT+: Pharmalittle: We’re reading about an FDA panel and peptides, a Merck license for an HIV pill, and more
In a win for peptide proponents, an FDA advisory panel recommended compounding pharmacies be allowed to make four of…
Read at source →
A new, separate outbreak of the diarrhea-causing parasite
A win for peptide proponents, autism advisory committees clash, and more health news from Morning Rounds
Read at source →
STAT+: Merck strikes voluntary licensing deals in poor countries for an experimental HIV prevention pill
Merck is striking licensing deals for its experimental HIV prevention pill in hope of getting wide-scale production…
Read at source →
STAT+: White House offers its science blueprint: More AI, less life sciences
The Trump administration released its blueprint for U.S. science, calling for shifting hundreds of billions of research…
Read at source →
Senate advances MAHA-friendly bill for food warning labels and junk food ad bans
Unexpected alliances among Republicans and Democrats were on display over a bill meant to rein in ultra-processed foods.
Read at source →
Opinion: The U.S. pharmaceutical supply chain problem is not about China
The national security framing of the discussion around pharmaceutical supply chain vulnerabilities is a distraction,…
Read at source →
Opinion: I may be one of the last middle-class medical students who could afford to become a doctor
A federal loan program made it possible for Gauri Gurumurthy to pursue medicine. Now that program is changing.
Read at source →
STAT+: In win for RFK Jr., FDA advisory panel narrowly votes to allow compounding of unapproved peptides
The panel recommended allowing compounding pharmacies to produce popular but unproven BPC-157 and KPV peptides.
Read at source →U.S. health officials are investigating a new outbreak of a diarrhea-causing parasite
Federal health officials are investigating a new outbreak involving the diarrhea-causing parasite cyclospora.
Read at source →
STAT+: European regulators take steps to bolster clinical trial transparency
The European Medicines Agency is taking what advocacy groups are calling unexpectedly “rapid action” to ensure that…
Read at source →
STAT+: Popular insulin product enters shortage as other pens leave market
The Lantus Solostar insulin pen isn't in official FDA shortage, but patients are having a tough time finding it.
Read at source →
Senate health panel delays vote on CDC nominee
Too few senators were in attendance to proceed with a vote on the CDC director nominee.
Read at source →
STAT+: What’s in the last-minute flurry of health care bills?
Congress is scrambling to advance a slew of health care bills before an August recess. Price transparency and prior…
Read at source →
FDA panel confronting peptide controversy
Today's biotech news features the FDA weighing the fate of peptides; approvals for RevMed, GSK; and data on Lilly's…
Read at source →
A father’s mission to save his daughter, and allegations on telehealth GLP-1 prescribing
Has a wanted fugitive been posing as a biotech executive? And what does it take to develop a therapy for an ultra-rare…
Read at source →
STAT+: Vote on key federal health nominee delayed amid questions over vaccine views
Sean Kaufman, nominated to run ASPR, has a track record of questioning the safety of vaccines.
Read at source →
STAT+: Trump administration quietly picks Timothy Westlake to lead mental health agency
Timothy Westlake, an emergency doctor nominated to head SAMHSA, has been active in addiction policy in Wisconsin.
Read at source →STAT+: Pharmalittle: We’re reading about Lilly obesity drug data, a push for FDA to ban DTC ads, and more
A study of Lilly's retatrutide weight loss drug in people with heart disease did not answer a crucial question —…
Read at source →
STAT+: HHS to convene experts on standards for clinical AI
In this edition of STAT Health Tech: HHS is inviting experts to shape policy on clinical AI, Whoop's new CMO, news…
Read at source →
STAT+: FDA is urged by advocacy group to ban DTC prescription drug ads
A leading advocacy group petitioned the FDA to ban direct-to-consumer advertising of prescription medicines.
Read at source →